Cargando…
Safety, tolerability and impact on viral reservoirs of the addition to antiretroviral therapy of ABX464, an investigational antiviral drug, in individuals living with HIV-1: a Phase IIa randomised controlled study
OBJECTIVES: To assess the safety and tolerability as well as antiretroviral impact of ABX464, an oral investigational drug with a novel mechanism of HIV-1 inhibition (ClinicalTrials.gov NCT02735863). METHODS: Randomised, double-blind, placebo-controlled, Phase IIa study in individuals living with HI...
Autores principales: | Rutsaert, Sofie, Steens, Jean-Marc, Gineste, Paul, Cole, Basiel, Kint, Sam, Barrett, P Noel, Tazi, Jamal, Scherrer, Didier, Ehrlich, Hartmut J, Vandekerckhove, Linos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mediscript Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362909/ https://www.ncbi.nlm.nih.gov/pubmed/30800421 |
Ejemplares similares
-
Safety, Pharmacokinetics, and Antiviral Activity of a Novel HIV Antiviral, ABX464, in Treatment-Naive HIV-Infected Subjects in a Phase 2 Randomized, Controlled Study
por: Steens, Jean-Marc, et al.
Publicado: (2017) -
ABX464 (Obefazimod) Upregulates miR-124 to Reduce Proinflammatory Markers in Inflammatory Bowel Diseases
por: Apolit, Cécile, et al.
Publicado: (2022) -
RNA sequencing analysis of activated macrophages treated with the anti-HIV ABX464 in intestinal inflammation
por: Manchon, Laurent, et al.
Publicado: (2017) -
The Anti-Hiv Candidate Abx464 Dampens Intestinal Inflammation by Triggering Il-22 Production in Activated Macrophages
por: Chebli, Karim, et al.
Publicado: (2017) -
Both anti-inflammatory and antiviral properties of novel drug candidate ABX464 are mediated by modulation of RNA splicing
por: Vautrin, Audrey, et al.
Publicado: (2019)